Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 May 26:2018:bcr2018224397.
doi: 10.1136/bcr-2018-224397.

Seronegative enteropathy and malnutrition: a diagnostic challenge

Affiliations
Case Reports

Seronegative enteropathy and malnutrition: a diagnostic challenge

James McCulloch et al. BMJ Case Rep. .

Abstract

A 21-year-old woman presented with a 2-week history of vomiting, diarrhoea and epigastric pain, with 9 kg weight loss over the last two months. Laboratory tests were normal with negative coeliac serology. Duodenal biopsies revealed total villous atrophy, crypt hypertrophy and intraepithelial lymphocytosis. A diagnosis of seronegative coeliac disease was made, and she started a gluten-free diet. However, she did not respond and her weight fell to 30.6 kg (body mass index 11), becoming dependent on parenteral nutrition. Her diagnosis was reconsidered and the histology reviewed. The histopathological features were of severe active chronic duodenitis. By diagnosis of exclusion, with the absence of other clear pathology, she was treated as Crohn's disease. She responded to third-line therapy with biologics. In this case, the patient had refractory villous atrophy and the mucosal features, in addition to response with anti-tumour necrosis factor therapy, suggest inflammatory bowel disease, although not with complete diagnostic certainty.

Keywords: crohn’s disease; gastrointestinal system; malabsorption; malnutrition; parenteral / enteral feeding.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Histology from a duodenal 2 biopsy displaying total villous atrophy, crypt hypertrophy, widespread moderate active chronic inflammation and moderate intraepithelial lymphocytosis.
Figure 2
Figure 2
Capsule endoscopy pre-adalimumab demonstrating loss of normal villous architecture.
Figure 3
Figure 3
Capsule endoscopy of the jejunum 18months post starting adalimumab demonstrating regeneration of villous architecture.

References

    1. Pisapia L, Camarca A, Picascia S, et al. . HLA-DQ2.5 genes associated with celiac disease risk are preferentially expressed with respect to non-predisposing HLA genes: implication for anti-gluten T cell response. J Autoimmun 2016;70:63–72. 10.1016/j.jaut.2016.03.016 - DOI - PubMed
    1. Aziz I, Peerally MF, Barnes JH, et al. . The clinical and phenotypical assessment of seronegative villous atrophy; a prospective UK centre experience evaluating 200 adult cases over a 15-year period (2000-2015). Gut 2017;66:1563–72. 10.1136/gutjnl-2016-312271 - DOI - PubMed
    1. Rubio-Tapia A, Herman ML, Ludvigsson JF, et al. . Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc 2012;87:732–8. 10.1016/j.mayocp.2012.06.003 - DOI - PMC - PubMed
    1. Basson M, Mezzarobba M, Weill A, et al. . Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study. Gut 2016;65:1664–9. 10.1136/gutjnl-2015-309690 - DOI - PubMed
    1. DeGaetani M, Tennyson CA, Lebwohl B, et al. . Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma. Am J Gastroenterol 2013;108:647–53. 10.1038/ajg.2013.45 - DOI - PubMed

Publication types

Substances